Shots:
- The EC has approved Vevzuo & Evfraxy, biosimilar versions of Amgen’s Xgeva & Prolia (denosumab) following the CHMP positive opinion in Apr 2025
- Approval was based on the comprehensive clinical data, which showed comparable PK, safety, efficacy & immunogenicity of Vevzuo & Evfraxy to the reference product
- Vevzuo prevents SREs in adults with bone-involved malignancies & treats unresectable or high-morbidity giant cell tumors of bone in adults & skeletally mature adolescents, while Evfraxy treats osteoporosis in postmenopausal women & men at high risk of fracture, & bone loss in pts on long-term glucocorticoids as well as in prostate cancer pts on hormone ablation
Ref: Biocon Biologics | Image: Biocon Biologics| Press Release
Related News:- Biocon Biologics Reports the Health Canada’s NOC for Yesafili (Biosimilar, Eylea)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
